Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

861 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG. Turtle CJ, et al. Among authors: byrd jc. J Clin Oncol. 2017 Sep 10;35(26):3010-3020. doi: 10.1200/JCO.2017.72.8519. Epub 2017 Jul 17. J Clin Oncol. 2017. PMID: 28715249 Free PMC article. Clinical Trial.
Advances in the therapy of chronic lymphocytic leukemia.
Johnson AJ, Mone AP, Abhyankar V, Byrd JC. Johnson AJ, et al. Among authors: byrd jc. Curr Opin Hematol. 2003 Jul;10(4):297-305. doi: 10.1097/00062752-200307000-00008. Curr Opin Hematol. 2003. PMID: 12799536 Review.
Rituximab in B-cell chronic lymphocytic leukemia.
Lin TS, Lucas MS, Byrd JC. Lin TS, et al. Among authors: byrd jc. Semin Oncol. 2003 Aug;30(4):483-92. doi: 10.1016/s0093-7754(03)00239-2. Semin Oncol. 2003. PMID: 12939717 Review.
Chronic lymphocytic leukemia.
Byrd JC, Stilgenbauer S, Flinn IW. Byrd JC, et al. Hematology Am Soc Hematol Educ Program. 2004:163-83. doi: 10.1182/asheducation-2004.1.163. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561682 Review.
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G, Stock W, Dai G, Klisovic RB, Liu S, Klisovic MI, Blum W, Kefauver C, Sher DA, Green M, Moran M, Maharry K, Novick S, Bloomfield CD, Zwiebel JA, Larson RA, Grever MR, Chan KK, Byrd JC. Marcucci G, et al. Among authors: byrd jc. J Clin Oncol. 2005 May 20;23(15):3404-11. doi: 10.1200/JCO.2005.09.118. Epub 2005 Apr 11. J Clin Oncol. 2005. PMID: 15824414 Clinical Trial.
861 results